secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040241
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana reports Q4 net loss $49.1M; positive T1D islet cell data at 12 weeks
-------------------------------------------------------------------------

- HIP-modified islet cells (UP421) produced C-peptide and MMTT response at 12 weeks without immunosuppression; no safety issues.
- Cash $152.5M at Dec 31, 2024; cash runway expected into 2026.
- Net loss $49.1M in Q4 2024 vs $88.1M in Q4 2023; full year 2024 net loss $266.8M.
- Enrolling GLEAM (SC291 autoimmune) and VIVID (SC262 B-cell cancers); data expected in 2025.
- Appointed Dhaval Patel as CSO and Tricia Stewart as CPO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017025040241/0000950170-25-040241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017025040241/sana-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer